These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 911030)

  • 1. Results of BCG adjuvant immunotherapy in 100 patients with epidermoid carcinoma of the head and neck.
    Suen JY; Richman SP; Livingston RB; Hersh EM; Craig R; Tonymon K
    Am J Surg; 1977 Oct; 134(4):474-8. PubMed ID: 911030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemotherapy versus chemoimmunotherapy of head and neck cancer: report of a randomized study.
    Richman SP; Livingston RB; Gutterman JU; Suen JY; Hersh EM
    Cancer Treat Rep; 1976 May; 60(5):535-9. PubMed ID: 62613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A controlled study of combined methotrexate, BCG, and INH therapy for squamous cell carcinoma of the head and neck.
    Woods JE; DeSanto LW; Ritts RE
    Surg Clin North Am; 1977 Aug; 57(4):769-78. PubMed ID: 897965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized trial of adjuvant BCG immunotherapy in head and neck cancer.
    Taylor SG; Sisson GA; Bytell DE; Raynor WJ
    Arch Otolaryngol; 1983 Aug; 109(8):544-9. PubMed ID: 6347154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
    Saba NF; Mody MD; Tan ES; Gill HS; Rinaldo A; Takes RP; Strojan P; Hartl DM; Vermorken JB; Haigentz M; Ferlito A
    Crit Rev Oncol Hematol; 2017 Jul; 115():50-58. PubMed ID: 28602169
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune reactivity in head and neck squamous carcinoma and relevance to the design of immunotherapy trials.
    Browder JP; Chretien PB
    Semin Oncol; 1977 Dec; 4(4):431-9. PubMed ID: 339354
    [No Abstract]   [Full Text] [Related]  

  • 7. High dose methotrexate with and without BCG therapy in advanced head and neck malignancy.
    Buechler M; Mukherji B; Chasin W; Nathanson L
    Cancer; 1979 Mar; 43(3):1095-100. PubMed ID: 311679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The controversial role of BCG in the treatment of squamous cell carcinoma of the head and neck.
    Medina JE
    Arch Otolaryngol; 1983 Aug; 109(8):543. PubMed ID: 6870648
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to docetaxel and cisplatin induction chemotherapy of locally advanced head and neck squamous cell carcinoma: a multicenter, non-comparative, open-label interventional pilot study.
    Noronha V; Goswami C; Patil S; Joshi A; Patil VM; Murthy V; Arya S; Juvekar S; Goud S; Prabhash K
    J Laryngol Otol; 2016 Sep; 130(9):833-42. PubMed ID: 27456399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Intratumor immunotherapy with BCG cell wall preparations: development of a new therapy approach for head-neck tumors].
    Bier J; Kleinschuster S; Bier H; Rapp H
    Arch Otorhinolaryngol; 1982; 236(3):245-55. PubMed ID: 7159277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlled trial of methotrexate and Bacillus Calmette-Guérin therapy for advanced head and neck cancer.
    Papac R; Minor DR; Rudnick S; Solomon LR; Capizzi RL
    Cancer Res; 1978 Oct; 38(10):3150-3. PubMed ID: 356962
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemoimmunotherapy in advanced lesions of the head and neck.
    Eilber FR; Morton DL
    AJR Am J Roentgenol; 1976 May; 126(5):1082-7. PubMed ID: 178233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy in the management of squamous-cell carcinoma of the head and neck.
    Lamont EB; Vokes EE
    Lancet Oncol; 2001 May; 2(5):261-9. PubMed ID: 11905780
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T-cell rosette test in squamous cell carcinoma of the head and neck.
    Eastham RJ; Mason JM; Jennings BR; Belew PW; Maguda TA
    Arch Otolaryngol; 1976 Mar; 102(3):171-5. PubMed ID: 1083730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of BCG adjuvant immunotherapy for melanoma of the head and neck.
    Eilber FR; Townsend CM; Morton DL
    Am J Surg; 1976 Oct; 132(4):476-9. PubMed ID: 1015538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of combined immunotherapy with levamisole and Bacillus Calmette-Guérin on immunocompetence of patients with squamous cell carcinoma of the cervix, head and neck, and lung undergoing radiation therapy.
    Olkowski ZL; McLaren JR; Skeen MJ
    Cancer Treat Rep; 1978 Nov; 62(11):1651-61. PubMed ID: 310339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy for Head and Neck Squamous Cell Carcinoma: A Review of Current and Emerging Therapeutic Options.
    Moskovitz JM; Moy J; Seiwert TY; Ferris RL
    Oncologist; 2017 Jun; 22(6):680-693. PubMed ID: 28507203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BCG immune activation reduces growth and angiogenesis in an in vitro model of head and neck squamous cell carcinoma.
    Sánchez-Rodríguez C; Cruces KP; Riestra Ayora J; Martín-Sanz E; Sanz-Fernández R
    Vaccine; 2017 Nov; 35(47):6395-6403. PubMed ID: 29029943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Treatment for Squamous Cell Carcinoma of the Head and Neck.
    Shetty AV; Wong DJ
    Otolaryngol Clin North Am; 2017 Aug; 50(4):775-782. PubMed ID: 28755705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The latest prospects of investigational drugs for head and neck cancer.
    Elicin O; Ozsahin M
    Expert Opin Investig Drugs; 2017 Mar; 26(3):265-268. PubMed ID: 28056562
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.